Wuhan Hualong Bio-Chemical Pharmaceutical

Wuhan Hualong Bio-Chemical Pharmaceutical is a Chinese pharmaceutical company specializing in the research, development, and manufacturing of biochemical drugs, particularly in the fields of cardiovascular, cerebrovascular, and digestive health. Founded in 1993 and now a subsidiary of Humanwell Healthcare, the company produces a wide range of products including oxiracetam, alprostadil, and various enzyme-based therapies like urokinase and chymotrypsin. Their facilities are GMP-certified, supporting the production of both active pharmaceutical ingredients (APIs) and finished dosage forms such as injections and lyophilized powders. The company maintains a strong presence in the domestic Chinese market while leveraging its parent organization's global network for broader reach.